retatrutide mechanism glp-1 gip glucagon triple agonist review 2024 2025 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. Phase 2 trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing ✨ RETATRUTIDE — The Next

One of the biggest concerns among healthcare professionals is that once the peptide promotes melanogenesis (the production of melanin) theres no way to stop the continuing production of melanin

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al

We offer quick-access supplements like GLP-1 Daily Support supplement to help bridge the gap

Selected vitamins and minerals in diabetes (technical review)

You can access your card via the SingleCare app for convenience as well

We fine-tune your medication, address underlying metabolic factors, and provide nutrition and lifestyle guidance to support both short-term weight loss and long-term maintenance